News | October 16, 2025
Syngene International invests in peptide laboratory in Bengaluru
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
